These aren't marketing lines. Each one is checkable against a published record.
Every batch is HPLC-verified to 99.9%, and the certificate is public before the lot ships.
Clinical dosing with no proprietary blends. What the label says is what the assay finds.
Lyophilized, nitrogen-flushed, and moved cold. Potency on arrival, not at the factory door.
Third-party results for every lot, linked from the QR on the cap. Scan it, read it, keep it.
Assayed on every batch.
Shipped and confirmed.
Door to door, logged.
One per lot, public.
Nitrogen-flushed, light-safe and traceable to its batch record. Certificate of analysis in every box.
| PRODUCT | CATEGORY | SPECIFICATION | FROM (USD) |
|---|
The target peptide is specified to the residue.
Solid-phase synthesis under GMP controls.
HPLC and mass-spec on every batch; results published.
Lyophilized, sealed and sent cold-chain.
Every vial's QR resolves here. Enter the code printed on your cap.
| LOT | PEPTIDE | HPLC PURITY | RELEASED | CERTIFICATE |
|---|---|---|---|---|
| PEP-0412 | BPC-157 · 5 mg | 99.42% | 03 Jun 2026 | CoA ↓ |
| PEP-0411 | Semaglutide · 5 mg | 99.31% | 28 May 2026 | CoA ↓ |
| PEP-0410 | Ipamorelin · 5 mg | 99.58% | 21 May 2026 | CoA ↓ |
| PEP-0409 | GHK-Cu · 50 mg | 98.77% | 15 May 2026 | CoA ↓ |
| PEP-0408 | Tirzepatide · 10 mg | 99.24% | 09 May 2026 | CoA ↓ |
Founded by two synthesis chemists in Austin.
GMP suite comes online; first published CoA.
Lot 500 released; cold-chain network across US and EU.
Series 01 — the first retail line, 500 protocols.
First run is limited to 500 protocols. Reserved in order of checkout.
Shop Series 01